8-Hydroxy-2'-deoxyguanosine (Synonyms: 8-OHdG) |
| カタログ番号GC40926 |
8-ヒドロキシ-2'-デオキシグアノシンは、酸化ストレスと発がんの重要なバイオマーカーです。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 88847-89-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
8-Hydroxy-2'-deoxyguanosine is a key biomarker of oxidative stress-induced DNA damage, used to assess the risk of various cancers and degenerative diseases[1]. 8-Hydroxy-2'-deoxyguanosine is produced when reactive oxygen species (such as hydroxyl radicals and peroxynitrite) attack the guanine base in DNA molecules, and can lead to G:C→T:A transversions during DNA replication, thereby playing an important role in gene mutation, carcinogenesis, and cellular senescence[2]. 8-Hydroxy-2'-deoxyguanosine serves as a biomarker for evaluating the extent of DNA damage in humans exposed to carcinogens such as tobacco smoke, asbestos fibers, heavy metals, and polycyclic aromatic hydrocarbons[3]. The concentration of 8-Hydroxy-2'-deoxyguanosine in the urine of cancer patients is significantly higher than in healthy adults, showing a positive correlation with malignant tumors, thus 8-Hydroxy-2'-deoxyguanosine can be used as a potential auxiliary indicator for tumor diagnosis[4].
In vitro, pretreatment of fully differentiated 3T3-L1 adipocytes with 8-Hydroxy-2'-deoxyguanosine (100μg/mL) for 1 hour, followed by stimulation with TNFα (10ng/mL) for 24 hours, significantly restored insulin-induced Akt phosphorylation levels and suppressed TNFα-induced JNK phosphorylation activation. When 3T3-L1 preadipocytes were treated with 8-Hydroxy-2'-deoxyguanosine (100μg/mL) every other day for 6 days during the differentiation induction phase, 8-Hydroxy-2'-deoxyguanosine significantly inhibited the mRNA expression of aP2, C/EBPα, and PPARγ, and reduced the number and size of mature adipocytes[5].
In vivo, 8-Hydroxy-2'-deoxyguanosine (30mg/kg/day) was administered orally to ApoE knockout mice that had undergone partial carotid artery ligation, for 2 weeks. 8-Hydroxy-2'-deoxyguanosine significantly inhibited high-fat diet-induced atherosclerotic plaque formation and reduced vascular lumen obstruction[6]. In Balb/c nude mice carrying KG-1 human acute myeloid leukemia cell-derived sarcomas, daily intraperitoneal injection of 8-Hydroxy-2'-deoxyguanosine (3.3-330mg/kg/day) for 14 days significantly inhibited KG-1 tumor growth in a dose-dependent manner, as evidenced by reduced tumor volume and weight[7].
References:
[1] AbuArrah M, Yuli Setianto B, Faisal A, et al. 8-Hydroxy-2-Deoxyguanosine as Oxidative DNA Damage Biomarker of Medical Ionizing Radiation: A Scoping Review. J Biomed Phys Eng. 2021 Jun 1;11(3):389-402.
[2] Di Minno A, Turnu L, Porro B, et al. 8-Hydroxy-2-deoxyguanosine levels and heart failure: A systematic review and meta-analysis of the literature. Nutr Metab Cardiovasc Dis. 2017 Mar;27(3):201-208.
[3] Kroese LJ, Scheffer PG. 8-hydroxy-2'-deoxyguanosine and cardiovascular disease: a systematic review. Curr Atheroscler Rep. 2014 Nov;16(11):452.
[4] Alarcón-Sánchez MA, Escoto-Vasquez LS, Heboyan A. Salivary 8-hydroxy-2'-deoxyguanosine levels in patients with oral cancer: a systematic review and meta-analysis. BMC Cancer. 2024 Aug 6;24(1):960.
[5] Huh JY, Jung I, Piao L, et al. 8-Hydroxy-2-deoxyguanosine ameliorates high-fat diet-induced insulin resistance and adipocyte dysfunction in mice. Biochem Biophys Res Commun. 2017 Sep 30;491(4):890-896.
[6] Huh JY, Son DJ, Lee Y, et al. 8-Hydroxy-2-deoxyguanosine prevents plaque formation and inhibits vascular smooth muscle cell activation through Rac1 inactivation. Free Radic Biol Med. 2012 Jul 1;53(1):109-21.
[7] Choi S, Choi HH, Choi JH, et al. Inhibitory effect of 8-oxo-7,8-dihydro-2'-deoxyguanosine on the growth of KG-1 myelosarcoma in Balb/c nude mice. Leuk Res. 2006 Nov;30(11):1425-36.
| Cell experiment [1]: | |
Cell lines | 3T3-L1 mouse preadipocytes |
Preparation Method | 3T3-L1 preadipocytes were maintained and differentiated in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS). For adipogenesis studies, 100μg/mL 8-Hydroxy-2'-deoxyguanosine was administered every other day for 6 days, starting 2 days prior to differentiation induction. For insulin signaling assays, fully differentiated adipocytes were pretreated with 100μg/mL 8-Hydroxy-2'-deoxyguanosine for 1 hour before stimulation with TNFα (10ng/mL, 24 hours) or insulin (1nM, 10 minutes). |
Reaction Conditions | 100μg/mL; 6 days (adipogenesis) or 1-hour pretreatment (insulin signaling). |
Applications | 8-Hydroxy-2'-deoxyguanosine significantly inhibited adipocyte differentiation by downregulating key adipogenic transcription factors (aP2, C/EBPα, and PPARγ) and reducing mature adipocyte size and number. 8-Hydroxy-2'-deoxyguanosine reversed TNFα-induced insulin resistance by restoring insulin-stimulated Akt phosphorylation and suppressed TNFα-activated JNK phosphorylation. Additionally, 8-Hydroxy-2'-deoxyguanosine time-dependently activated AMPK phosphorylation, indicating a role in metabolic regulation. |
| Animal experiment [2]: | |
Animal models | ApoE knockout (KO) mice |
Preparation Method | Mice were subjected to partial carotid ligation surgery at 8 weeks of age, where three caudal branches of the left common carotid artery (LCA) were ligated to induce disturbed flow. Mice were fed a high-fat diet (Paigen diet) immediately after surgery. 8-Hydroxy-2'-deoxyguanosine (30mg/kg/day) was administered orally via gavage once daily, starting 2 days before ligation and continuing for 14 days. Control groups received distilled water. |
Dosage form | 30mg/kg/day; oral gavage. |
Applications | 8-Hydroxy-2'-deoxyguanosine significantly reduced atherosclerotic plaque formation in the partially ligated LCA, as evidenced by decreased lesion area and prevented lumen occlusion. It inhibited superoxide production, reduced monocyte/macrophage infiltration, and attenuated extracellular matrix (ECM) accumulation |
References: | |
| Cas No. | 88847-89-6 | SDF | |
| 同義語 | 8-OHdG | ||
| Canonical SMILES | NC(N1[H])=NC(N([C@H]2C[C@H](O)[C@@H](CO)O2)C(N3)=O)=C3C1=O | ||
| Formula | C10H13N5O5 | M.Wt | 283.2 |
| 溶解度 | 0.1 M HCl: >10 mg/ml,DMF: 30 mg/ml,DMSO: 20 mg/ml,PBS pH 7.2: 3 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5311 mL | 17.6554 mL | 35.3107 mL |
| 5 mM | 706.2 μL | 3.5311 mL | 7.0621 mL |
| 10 mM | 353.1 μL | 1.7655 mL | 3.5311 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >96.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *